Overview

This trial is active, not recruiting.

Condition copd
Sponsor AstraZeneca
Start date March 2015
End date December 2016
Trial size 1250 participants
Trial identifier NCT02346292, NIS-RRU-XXX-2014/1

Summary

The study is an observational multicenter descriptive study. It is planned to enroll approximately 1250 subjects with severe and very severe COPD hospitalized for the reason of COPD exacerbation into departments of pulmonology or therapy. The study will be conducted in approximately 20-25 institutions of treatment and prevention in Russian Federation and will include about 50 to 60 subject at each clinical site.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case-only
Time perspective retrospective
Arm
Patients of both genders aged 40 years and older, smokers, with smoking history more than 10 pack-years, with severe and very severe COPD who were hospitalized with COPD exacerbation

Primary Outcomes

Measure
Percentage of subjects with severe and very severe COPD who received prescription of therapy, including different schemes of inhaled glucocorticoids use, according to main principles of COPD therapy (GOLD 2014 recommendations)
time frame: up to 12 months

Secondary Outcomes

Measure
Description of social characteristics (days of disability, etc.), economical status of subjects if applicable (if patient agreed) (average monthly income) with severe and very severe COPD hospitalized for the reason of COPD exacerbation
time frame: at the time of 1st visit
% of subjects with severe and very severe COPD for whom scheme of inhaled glucocorticoids use was changed after 3, 6, 9, and 12 months of follow-up (outpatient conditions after discharge from the hospital)
time frame: at the moment of discharge and after 3, 6, 9, and 12 months of follow-up
Frequency and reasons of treatment scheme correction during follow-up after its prescription at the moment of discharge from the hospital
time frame: at the moment of discharge and after 3, 6, 9, and 12 months of follow-up
% of subjects with severe and very severe COPD who during the follow-up period attended medical institution for the correction of treatment scheme prescribed at the moment of discharge from the hospital
time frame: at the moment of discharge and after 3, 6, 9, and 12 months of follow-up
% of subjects with severe and very severe COPD, received treatment with short acting anticholinergic drugs, SABA, LABA, LAMA, oral CS, FDC, phosphodiesterase type 4 inhibitors, theophylline
time frame: at the moment of discharge and after 3, 6, 9, and 12 months of follow-up
% of patients with asthma-COPD overlap syndrome among all subjects with severe and very severe COPD hospitalized for the reason of COPD exacerbation
time frame: at the time of 1st visit and 12 months of follow-up
% of subjects with asthma-COPD overlap syndrome who received treatment with inhaled glucocorticoids both
time frame: at the moment of discharge and after 3, 6, 9, and 12 months of follow-up
% of patients with severe and very severe COPD, who received treatment with short acting anticholinergic drugs, SABA, LABA, LAMA, oral CS, FDC, phosphodiesterase type 4 inhibitors, theophylline, among all subjects with ACOS
time frame: at the moment of discharge and after 3, 6, 9, and 12 months of follow-up
EQ-5D results
time frame: at the moment of discharge and after 3, 6, 9, and 12 months of follow-up
CAT results
time frame: at the moment of discharge and after 3, 6, 9, and 12 months of follow-up

Eligibility Criteria

Male or female participants at least 40 years old.

Inclusion Criteria: - Signed informed consent . Men and women at least 40 years old, with smoking history more than 10 pack-years. - Hospitalization for the reason of COPD exacerbation (exacerbation defined as acute condition, different from typical fluctuations of general condition and requiring change of therapy). - Diagnosis of severe or very severe COPD based on final spirometry (performed in a standardized manner using salbutamol 400 mg), or history of diagnosis of severe or very severe COPD based on spirometry performed during 6 months before the hospitalization. Exclusion Criteria: - Participation in any interventional study. - Concomitant respiratory diseases, i.e. confirmed or suspected malignancy or any other serious condition, including lung tumor, lung fibrosis, interstitial lung disease, tuberculosis, sarcoidosis. - Patient is unable or unwilling to complete questionnaires, unable to understand study procedures, or other reasons which, in the investigator's opinion, could affect study procedures performance.

Additional Information

Official title Observational Multicenter Non-interventional Study on COPD Patients Treatment Strategies at the Time of Hospital Discharge and Within 12 Months of Follow-up on an Outpatient Primary Care Basement
Principal investigator Sergey Avdeev, MD, PHD
Description The study is an observational multicenter descriptive study. It is planned to enroll approximately 1000 subjects with severe and very severe COPD hospitalized for the reason of COPD exacerbation into departments of pulmonology or therapy. The study will be conducted in approximately 20-25 institutions of treatment and prevention in Russian Federation and will include about 50 to 60 subject at each clinical site. This is an observational study, so there is no treatment protocol or subjects' management recommendations required. The study subjects receive medical treatment according to the routine practice for their disease in Russian Federation. A subject's participation in this clinical study should not affect character and amount of care provided according to the routine clinical practice. The study includes 5 clinical visits: Study Enrolment Visit, Month 3 Visit, Month 6 visit, Month 9 Visit, Month 12 visit / End of Study Visit.
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by AstraZeneca.